Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB500 in Advanced Solid Tumors
NCT06736327Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Dec 2024
- Primary completion
- Jul 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SKB500 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Adverse Events up to 3 years, Serious Adverse Events up to 3 years and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
SKB500
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06736327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736327.